Exscientia to start world-first trials of AI-designed immuno-oncology drug
Oxford-based AI drug discovery firm Exscientia is preparing to begin Phase I clinical trials with the world’s first AI-designed molecule for immuno-oncology.
Oxford-based AI drug discovery firm Exscientia is preparing to begin Phase I clinical trials with the world’s first AI-designed molecule for immuno-oncology.
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving…
ImmunityBio has reported initial data from Phase I clinical trial of its hAd5 Covid-19 vaccine candidate which stimulated the generation of T cell reactive to…
Global Healthcare Opportunities (GHO Capital) has signed an agreement to acquire US integrated clinical trial site organisation Velocity Clinical Research from NaviMed Capital and other…
Oxford-based AI drug discovery firm Exscientia is preparing to begin Phase I clinical trials with the world’s first AI-designed molecule…
Claritas Pharmaceuticals is set to expand its development programme for R-107 to include the treatment of Covid-19 related sepsis, which…
Laurent Pharmaceuticals has decided to continue the study of its pro-resolving drug LAU-7b without modification in the Phase II RESOLUTION…
BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after…
Amryt Pharma’s Juxtapid (lomitapide) had a 7-point jump in its Likelihood of Approval (LoA) in familial chylomicronaemia syndrome (FCS) on the heels of positive data from an investigator-led Phase III…
Johnson & Johnson’s Phase III double-dose Covid-19 vaccine prompted a range of expert analyses as to how the prime-boost regimen would be rolled out considering the single-dose approach is already…
The likelihood of approval (LoA) for AMO Pharma’s AMO-01 in Phelan-McDermid Syndrome (PMS) with co-morbid epilepsy jumped 13 points as of 29 March, according to GlobalData’s LoA data. The score change was…
THREAD, a tech-focused service provider that enables decentralised clinical trials, has recently penned a partnership with CureClick, a community-powered platform...
Akili Interactive has published data from its STARS-Adjunct trial supporting the efficacy of EndeavorRx, its attention-deficit hyperactivity disorder (ADHD) video game therapy for kids, in...
In a bid to put patient involvement at the heart of drug development and clinical trials, the Medicines and Healthcare products Regulatory Agency (MHRA) has...
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving at a matching pace. Clinical...
Sustained interest in oncology radiopharmaceuticals expected after positive results from 177Lu-PSMA-617 in prostate cancer
Radiopharmaceuticals play a niche role in treating cancer, despite having labels in multiple oncology indications in the US and EU, with few agents being commercially successful. In March, Novartis announced…